Interview Prof. Jordi Rejection
allautoe 0 GECP congresses entrevista news vídeo
In the session entitled “Peri-Operative Therapeutics”, Prof. Oncology expert Jordi Remon, he shared his opinion on the use of tyrosine-Cecine inhibitors (ITC, in Portuguese; TKIS) in the peroperative context. According to the expert, “we do not have current data that really supports the perioperative strategy with ITCs”, noting that existing data supports only the use of ITCs in the adjuvant context.
Prof. Jordi Remon stressed that the results obtained in the adjuvant context are impressive, but also acknowledged that there are challenges to be faced. Another relevant aspect addressed by the expert was the need to increase access to ITCs, considering their high cost.